PREVIOUS QUESTION:

 

NEXT QUESTION:

 

Can you use immunotherapy drugs together if you have lung cancer?

ANSWER

Early results hint that combining two checkpoint inhibitor immunotherapy drugs might be more effective than using just one. Doctors are also testing immunotherapy drugs for lung cancer that have been approved to treat other types, like melanoma. One of these drugs, ipilimumab (Yervoy), is being tested in combination with nivolumab to see if they work better together than chemotherapy alone.

SOURCES:

Cancer Support Community: “Frankly Speaking about Cancer: Treatments for Advanced and Metastatic Lung Cancer.”

National Comprehensive Cancer Network: “NCCN Guidelines for Patients: Lung Cancer/Non-Small Cell Lung Cancer.”

National Cancer Institute: “Biological Therapies for Cancer,” “Lung Cancer Precision Medicine Trials: Adapting to Progress,” “More Immunotherapy Options Approved for Lung Cancer,” “SEER Training Modules: “Combination Treatments,” “Targeted Cancer Therapies.”

Translational Lung Cancer Research : “Immunotherapy in Lung Cancer.”

Memorial Sloan Kettering Cancer Center: “Combination Immunotherapy Shows New Promise for Lung Cancer.”

Lungcancer.org: “Non-small Cell Lung Cancer Treatment.”

Cancer Immunology Research: “Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer.”

American Cancer Society: “Immunotherapy for non-small cell lung cancer,” “Targeted therapy drugs for non-small cell lung cancer.”

Lung Cancer Alliance: “Immunotherapy for Lung Cancer: A Guide for the Patient.”

FDA: “Atezolizumab (TECENTRIQ).”

Therapeutic Advances in Medical Oncology : “Checkpoint inhibitors in lung cancer: latest developments and clinical potential.”

Cancer Treatment Reviews : “The abscopal effect of local radiotherapy: using immunology to make a rare event clinically relevant.”

Cancer.net: “When the First Treatment Doesn’t Work.”

Reviewed by Laura J. Martin on August 21, 2019

SOURCES:

Cancer Support Community: “Frankly Speaking about Cancer: Treatments for Advanced and Metastatic Lung Cancer.”

National Comprehensive Cancer Network: “NCCN Guidelines for Patients: Lung Cancer/Non-Small Cell Lung Cancer.”

National Cancer Institute: “Biological Therapies for Cancer,” “Lung Cancer Precision Medicine Trials: Adapting to Progress,” “More Immunotherapy Options Approved for Lung Cancer,” “SEER Training Modules: “Combination Treatments,” “Targeted Cancer Therapies.”

Translational Lung Cancer Research : “Immunotherapy in Lung Cancer.”

Memorial Sloan Kettering Cancer Center: “Combination Immunotherapy Shows New Promise for Lung Cancer.”

Lungcancer.org: “Non-small Cell Lung Cancer Treatment.”

Cancer Immunology Research: “Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer.”

American Cancer Society: “Immunotherapy for non-small cell lung cancer,” “Targeted therapy drugs for non-small cell lung cancer.”

Lung Cancer Alliance: “Immunotherapy for Lung Cancer: A Guide for the Patient.”

FDA: “Atezolizumab (TECENTRIQ).”

Therapeutic Advances in Medical Oncology : “Checkpoint inhibitors in lung cancer: latest developments and clinical potential.”

Cancer Treatment Reviews : “The abscopal effect of local radiotherapy: using immunology to make a rare event clinically relevant.”

Cancer.net: “When the First Treatment Doesn’t Work.”

Reviewed by Laura J. Martin on August 21, 2019

NEXT QUESTION:

When should you change treatments for lung cancer?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.

    Other Answers On: